Brief: Aptose Starts Dosing Of Tuspetinib In Patients With Acute Myeloid Leukemia
30/01/2023 12:30
Jan 30 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE INITIATES DOSING OF TUSPETINIB IN APTIVATE
EXPANSION
TRIAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
* APTOSE BIOSCIENCES INC-ANOTHER CLINICAL RESPONSE ACHIEVED
BY R/R
AML PATIENT RECEIVING 40 MG TUSPETINIB ONCE DAILY ORALLY IN
ORIGINAL DOSE EXPLORATION TRIAL
Source text for Eikon: ID:nGNX5chZt9
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting